These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25983110)

  • 1. A conserved WW domain-like motif regulates invariant chain-dependent cell-surface transport of the NKG2D ligand ULBP2.
    Uhlenbrock F; van Andel E; Andresen L; Skov S
    Mol Immunol; 2015 Aug; 66(2):418-27. PubMed ID: 25983110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NKG2D ligand ULBP2 is specifically regulated through an invariant chain-dependent endosomal pathway.
    Uhlenbrock F; Hagemann-Jensen M; Kehlet S; Andresen L; Pastorekova S; Skov S
    J Immunol; 2014 Aug; 193(4):1654-65. PubMed ID: 25024379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
    Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
    J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
    Wittenbrink M; Spreu J; Steinle A
    Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
    Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
    Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
    Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
    Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands.
    Müller S; Zocher G; Steinle A; Stehle T
    PLoS Pathog; 2010 Jan; 6(1):e1000723. PubMed ID: 20090832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
    Heinemann A; Zhao F; Pechlivanis S; Eberle J; Steinle A; Diederichs S; Schadendorf D; Paschen A
    Cancer Res; 2012 Jan; 72(2):460-71. PubMed ID: 22102694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells.
    Fernández-Messina L; Ashiru O; Agüera-González S; Reyburn HT; Valés-Gómez M
    J Cell Sci; 2011 Feb; 124(Pt 3):321-7. PubMed ID: 21224393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner.
    Bálint Š; Lopes FB; Davis DM
    Sci Signal; 2018 Apr; 11(525):. PubMed ID: 29636390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
    Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
    Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity.
    Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W
    J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
    Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
    Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
    Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
    Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four novel ULBP splice variants are ligands for human NKG2D.
    Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
    Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D.
    Song H; Park H; Park G; Kim YS; Lee HK; Jin DH; Kang HS; Cho DH; Hur D
    Oncol Rep; 2014 Jul; 32(1):425-30. PubMed ID: 24841552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell.
    Bae DS; Hwang YK; Lee JK
    Cell Immunol; 2012; 276(1-2):122-7. PubMed ID: 22613008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Waldhauer I; Steinle A
    Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.